Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 52 of 5804
-
Could this new vaccine end tuberculosis?
⭐️ VACCINE ⭐️ Recruiting nowA Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region.
Phase: PHASE2 • Sponsor: International AIDS Vaccine Initiative • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:02 UTC
-
New pill aims to cut sickle cell pain crises in half
Disease control Recruiting nowThis study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Simple blood test could spot lung cancer early in heavy smokers
Diagnosis Recruiting nowThe goal of this observational study is to develop and evaluate a blood test for asymptomatic heavy smokers to screen for those at highest risk of developing lung cancer. The aim of this study is to develop, train, and validate a blood-based screening test designed to detect biom…
Sponsor: Everest Detection, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Mass Drug-Vaccine combo takes on malaria in 10,000-Person trial
Prevention Recruiting nowThis is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass vaccinations and drug administrations versus the curr…
Phase: PHASE4 • Sponsor: University of Oxford • Aim: Prevention
Last updated Jun 27, 2026 08:05 UTC
-
Engineered immune cells show promise in Hard-to-Treat leukemia
Disease control Recruiting nowThe safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL) subjects from the ATHENA trial (NCT06014073). Unexpect…
Phase: PHASE1, PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New CAR-T therapy targets tough T-Cell cancers in early trial
Disease control Recruiting nowTo observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
Phase: PHASE1, PHASE2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
ER-to-Home plan aims to slash opioid overdose deaths
Disease control Recruiting nowOpioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patie…
Phase: PHASE1, PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a pill replace chemo for advanced breast cancer? new trial aims to find out.
Disease control Recruiting nowThe DIAMOND study (DIAMOND-01) is a multicenter, randomized, open-label, non-inferiority Phase III clinical trial conducted by Fudan University Shanghai Cancer Center. The study aims to evaluate the efficacy and safety of an oral, "non-intravenous" regimen (pyrotinib + trastuzuma…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: Rina-S faces off against standard chemo in major trial
Disease control OngoingThis phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovaria…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a pill help stop breast cancer from spreading after a local return?
Disease control Recruiting nowThe JCOG2313 trial is a multicenter, randomized, phase III study designed to evaluate the efficacy and safety of adjuvant abemaciclib in combination with endocrine therapy versus endocrine therapy alone in patients with hormone receptor (HR)-positive, HER2-negative breast cancer …
Phase: PHASE3 • Sponsor: Japanese Foundation for Cancer Research • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Custom Gene-Targeting drug offers hope for one child with fatal brain disorder
Disease control OngoingThis research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Childhood-Onset Neurodegeneration with Brain Atrophy (CONDBA) due to a heterozygous missense gain-of-function mutation in UBTF
Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could buntanetap slow Alzheimer's? major trial underway
Disease control OngoingThe goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as…
Phase: PHASE3 • Sponsor: Annovis Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untr…
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Brain cancer patients get new hope: electric fields plus immunotherapy tested in major trial
Disease control Recruiting nowThis is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newl…
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug could shield preemie lungs from deadly disease
Prevention Recruiting nowThis is a randomized, parallel-group, double-blind, placebo-controlled multicenter phase 2b/3 study with an adaptive seamless design. The goal fo this study is to determine if an investigational drug, Zelpultide Alfa, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD)…
Phase: PHASE2, PHASE3 • Sponsor: Airway Therapeutics, Inc. • Aim: Prevention
Last updated Jul 17, 2026 00:00 UTC
-
Promising combo therapy for aggressive brain cancer enters final testing phase
Disease control Recruiting nowBackground: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months. The standard treatment involves surgery followed by radiation and chemotherapy with Temozolomide (TMZ). The efficacy of TMZ, however, is significant…
Phase: PHASE3 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Recruiting nowThe mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma
Phase: PHASE1, PHASE2 • Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells take on childhood cancer in new trial
Disease control Recruiting nowThis Phase 1/2 trial aims to determine the safety and feasibility of administration of autologous chimeric antigen receptor (CAR) T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor in pediatric subjects with relapsed or refractory neuroblastoma (NB). The trial…
Phase: PHASE1, PHASE2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Donor immune cells take on tough T-Cell cancers in new trial
Disease control Recruiting nowThe T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Phase: PHASE2 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New lung cancer drug aims to match Keytruda's success
Disease control OngoingThe goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.
Phase: PHASE3 • Sponsor: Celltrion • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC